<DOC>
	<DOCNO>NCT00545363</DOCNO>
	<brief_summary>This 2 arm study assess impact bone marker feedback ( BMF ) , use serum carboxy-terminal collagen crosslinks ( CTX ) communication result 3 month , adherence monthly ibandronate ( 150 milligram [ mg ] per oral [ po ] ) woman post-menopausal osteoporosis support patient-relationship program ( PRP ) . Participants randomize either receive BMF BMF ; group support PRP . The anticipated time study treatment 3-12 month .</brief_summary>
	<brief_title>A Study Adherence Once Monthly Ibandronate ( Bonviva ) Women With Post-Menopausal Osteoporosis , Supported Patient Relationship Program ( PRP )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>ambulatory , postmenopausal woman osteoporosis ; eligible bisphosphonate treatment ; na√Øve bisphosphonate therapy , lapse user ( last bisphosphonate intake great equal [ &gt; = ] 6 month ago ) . inability stand sit upright least 60 minute ; inability swallow tablet whole ; hypersensitivity bisphosphonates ; treatment drug , presence active disease , know influence bone metabolism ; history upper gastrointestinal disease .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>